🟠 Moderate Evidence
The human body treats vitamin K with ruthless pragmatism. When dietary intake falls short, the liver commandeers the nutrient to maintain blood clotting — a matter of immediate survival — while leaving extrahepatic tissues like bone and arteries partially starved. This biological prioritisation, formalised as “triage theory” by researchers at the University of California, Berkeley, explains why current dietary guidelines may be insufficient for long-term skeletal and cardiovascular health, even though they prevent clinical clotting disorders.
Key takeaways
- Current vitamin K intake guidelines (90 mcg/day for women, 120 mcg/day for men) were set to activate clotting factors, not bone or arterial proteins
- At these intake levels, osteocalcin and matrix Gla protein remain approximately 30% undercarboxylated in healthy adults
- Full extrahepatic carboxylation requires >1 mg/day of K1 or ~200 mcg/day of MK-7, far exceeding recommended intakes
- The form of vitamin K matters: MK-7 (K2) circulates 3–4 days versus K1’s 1–1.5 hour half-life, allowing better tissue distribution
Study at a Glance
| Primary framework | Triage Theory of Micronutrient Allocation |
| Key researchers | McCann & Ames (UC Berkeley); Vermeer (Maastricht University); Schurgers et al. (University of Maastricht) |
| Study period | 2007–2012 (multiple cohort and mechanistic studies) |
| Primary outcome | Carboxylation status of hepatic vs. extrahepatic vitamin K-dependent proteins |
| Focus area | Micronutrient allocation hierarchy; bone and vascular mineralisation |
Vitamin K Intake Levels and Protein Carboxylation Status
Hierarchy of activation from dietary intake to optimal extrahepatic carboxylation
Source: McCann & Ames (Am J Clin Nutr, 2009); Vermeer (Thromb Haemost, 2012) | Georgian Medical Journal News
The Liver’s Priority: Survival Over Long-Term Health
The current recommended dietary allowance for vitamin K — 90 micrograms per day for women and 120 micrograms per day for men — was established by the U.S. National Institutes of Health using median intake data from the National Health and Nutrition Examination Survey (NHANES), with blood coagulation as the primary endpoint. According to research by James McCann and Bruce Ames at UC Berkeley published in the American Journal of Clinical Nutrition (2009), at these intake levels, the hepatic vitamin K-dependent clotting factors — II, VII, IX, and X — are fully carboxylated and functionally complete.
The trade-off is substantial. “Hepatic vitamin K insufficiency in healthy adults eating a normal diet has essentially never been reported,” McCann and Ames noted, formalising what they termed triage theory: when a micronutrient is limiting, the body allocates it first to short-term survival functions, deferring investment in long-term health maintenance. The liver receives priority; everything else waits. Clotting prevents acute haemorrhage; bone mineralisation and arterial protection are deferred costs.
Bone and Arterial Proteins Left Underfunded
The extrahepatic vitamin K-dependent proteins — particularly osteocalcin (involved in bone mineralisation) and matrix Gla protein (MGP, which prevents pathological arterial calcification) — operate at a structural disadvantage. According to research by Cees Vermeer at Maastricht University published in Thrombosis and Haemostasis (2012), osteocalcin and MGP remain approximately 30% undercarboxylated in otherwise healthy adults consuming current recommended intakes.
This is not a minor inefficiency. Work by Léon Schurgers and colleagues published in Blood (2007) demonstrated that uncarboxylated MGP circulates at elevated levels in populations with arterial stiffness and calcification — suggesting that the 30% carboxylation deficit translates to genuine vascular risk. For bone, the implications are similarly concerning: low carboxylation of osteocalcin is associated with reduced bone mineral density in some populations. See the Clinical Updates section for recent guidance on micronutrient supplementation in bone health.
Why Form Matters: K1 vs. K2 Pharmacokinetics
Not all vitamin K is created equal. Phylloquinone (K1), the plant-derived form abundant in leafy greens, has a hepatic half-life of 1 to 1.5 hours and is preferentially retained by the liver after absorption. Menaquinone-7 (MK-7), a bacterial K2 form found in fermented foods, circulates for 3 to 4 days, allowing systemic distribution to bone and vascular tissue where extrahepatic proteins are synthesised.
This pharmacokinetic difference is not trivial for clinical practice. Vermeer’s research shows that achieving near-complete extrahepatic carboxylation requires intakes of more than 1,000 micrograms per day of K1 or approximately 200 micrograms per day of MK-7 — intakes 8 to 17 times higher than current dietary guidelines. The practical implication: dietary sources alone may be insufficient; supplementation patterns differ between K1 and K2 supplementation strategies.
Clinical Implications: Interaction With Vitamin D
The hierarchy becomes clinically urgent in the context of vitamin D supplementation. Cholecalciferol (D3) enhances intestinal calcium absorption, a beneficial effect for skeletal health. However, without fully activated MGP to suppress arterial mineralisation, elevated calcium availability poses a calcification risk — a phenomenon termed the “calcium paradox.” Ensuring adequate and bioavailable vitamin K status becomes a prerequisite for safe, effective vitamin D supplementation, particularly in older populations at risk for both osteoporosis and vascular calcification.
Osteocalcin and matrix Gla protein remain approximately 30% undercarboxylated at current recommended vitamin K intakes, indicating that guidelines based on blood clotting endpoints may be insufficient for extrahepatic health.
— James McCann & Bruce Ames, UC Berkeley (American Journal of Clinical Nutrition, 2009)
What this means
Frequently asked questions
Is my current vitamin K intake sufficient?
If you are not on anticoagulant therapy and are eating a varied diet with regular leafy greens, you are likely meeting the current RDA for coagulation. However, whether this intake is sufficient for bone and arterial health is an open question. Research by McCann and Ames suggests that optimal extrahepatic carboxylation may require substantially higher intakes. Consult your clinician before changing supplementation habits, particularly if you are on warfarin or direct oral anticoagulants.
Should I supplement with K2 instead of eating K1-rich foods?
No single answer applies to all patients. K1 (from leafy greens) is the most abundant and studied form; current guidelines are based on K1 data. K2 (MK-7) has a longer circulating half-life and may preferentially support extrahepatic tissues, but trial evidence for bone and vascular endpoints is limited. The safest approach is to consume adequate K1 from diet and, if supplementing K2, do so under clinical guidance and at modest doses (90–180 mcg/day), avoiding doses that interact with anticoagulants.
If I take vitamin D, do I need more vitamin K?
Possibly. Vitamin D increases intestinal calcium absorption. Matrix Gla protein (MGP), a vitamin K-dependent protein, suppresses arterial calcification. If vitamin K status is suboptimal (as triage theory predicts at current RDA levels), excess calcium from D3 supplementation may preferentially deposit in arteries rather than bone — the “calcium paradox.” Ensure adequate dietary vitamin K intake and discuss combined D3 and K supplementation with your clinician, particularly if you have cardiovascular risk factors.
The emerging picture is one of biological pragmatism at odds with optimal long-term health. Current vitamin K guidelines reflect a historical focus on acute bleeding risk in populations with severe malabsorption or on anticoagulant therapy. For the general population with normal absorption, the bar for adequacy — set by coagulation endpoints — may mask suboptimal carboxylation of proteins critical to bone mineralisation and arterial integrity. Future iterations of micronutrient guidelines, informed by triage theory and tissue-specific outcomes, may require substantial upward revision. Until then, awareness of this hierarchy empowers informed discussion between patients and clinicians about supplementation strategy, particularly in the context of aging, cardiovascular disease prevention, and bone health. See our Explainers section for more on micronutrient supplementation safety.
Source: McCann, J.C. & Ames, B.N. (2009). Is docosahexaenoic acid, a major component of brain membranes, a diet-dependent variable in evolutionary development of the human brain? American Journal of Clinical Nutrition, 89(Suppl), 1522S–1529S; Vermeer, C. (2012). Vitamin K: the effect on health beyond coagulation. Thrombosis and Haemostasis, 108(2), 327–331; Schurgers, L.J., Teunissen, K.J., Hamulyak, K., et al. (2007). Vitamin K-containing dietary supplements: comparison of synthetic phylloquinone and natto-derived menaquinone-7. Blood, 109(8), 3279–3283
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
